Intravenous Iron Dextran as a Component of Anemia Management in Chronic Kidney Disease: A Report of Safety and Efficacy

Table 2

Parameter comparison at three evaluation points in iron dextran group.

Parameter	Evaluation days	Group means ± SD		𝑃 value
Hb (g/dL)	Baseline versus day 30	9.4 ± 0.8	10.7 ± 1.0	<0.0001
	Baseline versus day 60	9.4 ± 0.8	11.3 ± 1.1	<0.0001
	Day 30 versus day 60	10.7 ± 1.0	11.3 ± 1.1	<0.0001
TSAT%	Baseline versus day 30	12.9 ± 4.0	23.4 ± 8.7	<0.0001
	Baseline versus day 60	12.9 ± 4.0	24.0 ± 9.9	<0.0001
	Day 30 versus day 60	23.4 ± 8.7	24.0 ± 9.9	<0.0001
	Baseline versus day 30	134.7 ± 151.5	359.0 ± 295.6	<0.0001
Ferritin (ng/mL)	Baseline versus day 60	134.7 ± 151.5	294.0 ± 254.6	<0.0001
	Day 30 versus day 60	359.0 ± 295.6	294.0 ± 254.6	0.0058